Activation of ANP synthesis during congestive heart failure in rats treated with monocrotaline

L. Comini, G. Agnoletti, A. Panzali, G. Mantero, E. Pasini, G. Gaia, A. Albertini, R. Ferrari

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We studied plasma concentration, content, and mRNA for atrial natriuretic peptide (ANP-mRNA) in heart chambers of monocrotaline-treated rats. Three distinct groups emerged: group 1, with moderate congestive heart failure (CHF; pleural effusion <1 ml; no peritoneal effusion); group 2, with severe CHF (pleural and peritoneal effusion > 1 ml); and group 3, with right hypertrophy and no CHF. Group 1 and 2 rats had right atrial and ventricular hypertrophy, raised plasma ANP (from 16.31 ± 11.32 to 98.50 ± 22.50 and 124.09 ± 57.29 pg/ml, respectively; P <0.001), and depletion of right atrial ANP (from 143.23 ± 29.79 to 21.70 ± 17.70 and 18.12 ± 14.64 nmol/g, respectively; P <0.001). Ventricular ANP concentration was unchanged. ANP- mRNA rose in the right atrium [10.6 (P <0.02) and 7.9 (P <0.01) times] and right ventricle (53.0 and 46.6 times; P <0.01). In left unhypertrophied chambers it also increased, although to a smaller extent. Group 3 rats had isolated right ventricular hypertrophy, normal ANP levels in plasma and tissues, and no activation of synthesis. These data suggest that 1) plasma concentration and ANP synthesis are increased only in animals with CHF, 2) activation of ANP synthesis is maximal in early stages of CHF and is not related to the degree of hypertrophy, and 3) ANP-mRNA is also expressed in unhypertrophied heart chambers of rats with CHF but is not expressed in hypertrophied chambers of animals without CHF.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume268
Issue number1 37-1
Publication statusPublished - 1995

Fingerprint

monocrotaline
Monocrotaline
Atrial Natriuretic Factor
heart failure
hypertrophy
Heart Failure
synthesis
rats
heart
atrial natriuretic peptide
Right Ventricular Hypertrophy
Messenger RNA
animals
Rosa
Hypertrophy
Pleural Effusion
Heart Atria
Heart Ventricles

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Physiology

Cite this

Activation of ANP synthesis during congestive heart failure in rats treated with monocrotaline. / Comini, L.; Agnoletti, G.; Panzali, A.; Mantero, G.; Pasini, E.; Gaia, G.; Albertini, A.; Ferrari, R.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 268, No. 1 37-1, 1995.

Research output: Contribution to journalArticle

Comini, L. ; Agnoletti, G. ; Panzali, A. ; Mantero, G. ; Pasini, E. ; Gaia, G. ; Albertini, A. ; Ferrari, R. / Activation of ANP synthesis during congestive heart failure in rats treated with monocrotaline. In: American Journal of Physiology - Heart and Circulatory Physiology. 1995 ; Vol. 268, No. 1 37-1.
@article{a9d4021eaad34c3ebd9639840110b489,
title = "Activation of ANP synthesis during congestive heart failure in rats treated with monocrotaline",
abstract = "We studied plasma concentration, content, and mRNA for atrial natriuretic peptide (ANP-mRNA) in heart chambers of monocrotaline-treated rats. Three distinct groups emerged: group 1, with moderate congestive heart failure (CHF; pleural effusion <1 ml; no peritoneal effusion); group 2, with severe CHF (pleural and peritoneal effusion > 1 ml); and group 3, with right hypertrophy and no CHF. Group 1 and 2 rats had right atrial and ventricular hypertrophy, raised plasma ANP (from 16.31 ± 11.32 to 98.50 ± 22.50 and 124.09 ± 57.29 pg/ml, respectively; P <0.001), and depletion of right atrial ANP (from 143.23 ± 29.79 to 21.70 ± 17.70 and 18.12 ± 14.64 nmol/g, respectively; P <0.001). Ventricular ANP concentration was unchanged. ANP- mRNA rose in the right atrium [10.6 (P <0.02) and 7.9 (P <0.01) times] and right ventricle (53.0 and 46.6 times; P <0.01). In left unhypertrophied chambers it also increased, although to a smaller extent. Group 3 rats had isolated right ventricular hypertrophy, normal ANP levels in plasma and tissues, and no activation of synthesis. These data suggest that 1) plasma concentration and ANP synthesis are increased only in animals with CHF, 2) activation of ANP synthesis is maximal in early stages of CHF and is not related to the degree of hypertrophy, and 3) ANP-mRNA is also expressed in unhypertrophied heart chambers of rats with CHF but is not expressed in hypertrophied chambers of animals without CHF.",
author = "L. Comini and G. Agnoletti and A. Panzali and G. Mantero and E. Pasini and G. Gaia and A. Albertini and R. Ferrari",
year = "1995",
language = "English",
volume = "268",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "1 37-1",

}

TY - JOUR

T1 - Activation of ANP synthesis during congestive heart failure in rats treated with monocrotaline

AU - Comini, L.

AU - Agnoletti, G.

AU - Panzali, A.

AU - Mantero, G.

AU - Pasini, E.

AU - Gaia, G.

AU - Albertini, A.

AU - Ferrari, R.

PY - 1995

Y1 - 1995

N2 - We studied plasma concentration, content, and mRNA for atrial natriuretic peptide (ANP-mRNA) in heart chambers of monocrotaline-treated rats. Three distinct groups emerged: group 1, with moderate congestive heart failure (CHF; pleural effusion <1 ml; no peritoneal effusion); group 2, with severe CHF (pleural and peritoneal effusion > 1 ml); and group 3, with right hypertrophy and no CHF. Group 1 and 2 rats had right atrial and ventricular hypertrophy, raised plasma ANP (from 16.31 ± 11.32 to 98.50 ± 22.50 and 124.09 ± 57.29 pg/ml, respectively; P <0.001), and depletion of right atrial ANP (from 143.23 ± 29.79 to 21.70 ± 17.70 and 18.12 ± 14.64 nmol/g, respectively; P <0.001). Ventricular ANP concentration was unchanged. ANP- mRNA rose in the right atrium [10.6 (P <0.02) and 7.9 (P <0.01) times] and right ventricle (53.0 and 46.6 times; P <0.01). In left unhypertrophied chambers it also increased, although to a smaller extent. Group 3 rats had isolated right ventricular hypertrophy, normal ANP levels in plasma and tissues, and no activation of synthesis. These data suggest that 1) plasma concentration and ANP synthesis are increased only in animals with CHF, 2) activation of ANP synthesis is maximal in early stages of CHF and is not related to the degree of hypertrophy, and 3) ANP-mRNA is also expressed in unhypertrophied heart chambers of rats with CHF but is not expressed in hypertrophied chambers of animals without CHF.

AB - We studied plasma concentration, content, and mRNA for atrial natriuretic peptide (ANP-mRNA) in heart chambers of monocrotaline-treated rats. Three distinct groups emerged: group 1, with moderate congestive heart failure (CHF; pleural effusion <1 ml; no peritoneal effusion); group 2, with severe CHF (pleural and peritoneal effusion > 1 ml); and group 3, with right hypertrophy and no CHF. Group 1 and 2 rats had right atrial and ventricular hypertrophy, raised plasma ANP (from 16.31 ± 11.32 to 98.50 ± 22.50 and 124.09 ± 57.29 pg/ml, respectively; P <0.001), and depletion of right atrial ANP (from 143.23 ± 29.79 to 21.70 ± 17.70 and 18.12 ± 14.64 nmol/g, respectively; P <0.001). Ventricular ANP concentration was unchanged. ANP- mRNA rose in the right atrium [10.6 (P <0.02) and 7.9 (P <0.01) times] and right ventricle (53.0 and 46.6 times; P <0.01). In left unhypertrophied chambers it also increased, although to a smaller extent. Group 3 rats had isolated right ventricular hypertrophy, normal ANP levels in plasma and tissues, and no activation of synthesis. These data suggest that 1) plasma concentration and ANP synthesis are increased only in animals with CHF, 2) activation of ANP synthesis is maximal in early stages of CHF and is not related to the degree of hypertrophy, and 3) ANP-mRNA is also expressed in unhypertrophied heart chambers of rats with CHF but is not expressed in hypertrophied chambers of animals without CHF.

UR - http://www.scopus.com/inward/record.url?scp=0028890872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028890872&partnerID=8YFLogxK

M3 - Article

C2 - 7840289

AN - SCOPUS:0028890872

VL - 268

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 1 37-1

ER -